FP7Individual fellowship2012–2014

MDR modulator · Synthesis and evaluation of new macrocyclic compounds based on jatrophane scaffold

FP7 — People (Marie Curie Actions)

Duration
2012-04-01 → 2014-03-31
EU contribution
€191,938
Participants
1
Scheme
MC-IEF

Lines connect the coordinator with its partners.

Results in brief

Synthesis and evaluation of new macrocyclic compounds based on jatrophane scaffold

Synthesis and evaluation of new macrocyclic compounds based on jatrophane scaffold Summary description of the project objectives: 1) Approach to the synthesis of new Multi Drug Resistance modulator 2) Preparation of natural product analogues and their evaluation as Multi Drug Resistance modulator 3) Biologically evaluation of chemically synthesized natural product analogues as anti-metastatic agents Description of the work performed since the beginning of the project and main results achieved so far. The occurrence of resistance to anticancer agents is a major obstacle for successful cancer chemotherapy. The emergence of resistance to anticancer drugs, in particular multidrug resistance (MDR) has made many of the available anticancer drugs ineffective. (1) MDR, is a complex multifactorial phenomenon that can result from a number of biochemical mechanisms. One of these possible mechanisms is the enhanced activity of various members of a family of (ABC)-transporters. ABCB1, also known as P-glycoprotein, transport the drug from inside to the outside of the cell. This reduces the cytotoxicity of the anticancer agent and enables the tumour cells to survive. MDR problem could be overcome by the inhibition of this transport system. (2) Jatrophane diterpene are a class of natural compounds, which were extracted from plants of the genus of Euphorbia. The phytopharmacological properties of the genus Euphorbia are well documented. A broad range of biological properties have been reported for constituents of the plant extract. (3) In particular, jatrophane have been found to be potent and specific P-glycoprotein modulators. (4) Our goal is to prepare new synthetic jatrophane analogues with an increased biological activity. As starting material, we decided to use the inexpensive monosaccharide L-sorbose. This monosaccharide is the starting material for the industrial synthesis of Vitamin C. Its production is approximately 60000 tons/year. Despite the similarity with the well exploited D-fructose, only a few methods have been developed for the modification of this readily available sugar. We decided to develop a new manipulation strategy and we applied this methodology for the preparation of an advanced intermediate that can be used for the preparation of a library of jatrophone analogues Final results and their potential impact and use A novel synthetic approach for the manipulation of L-sorbose was developed. An advanced intermediate for the preparation of potential Multi Drug Resistance Modulators was synthesized. Importantly, the synthetic route developed herein provided access to cyclopentitols (polyhydroxylated cyclopentanes) which are of particular significance because of their presence in a variety of medicinally relevant natural products. The synthetic route developed herein is expected to have a significant impact in the scientific community devoted to use of monosaccharides and their application in synthesis. The research is related to the use of materials from the chiral pool for synthesis. Synthesis of Migrastatin analogues. Migrastatin analogues were synthesized in order to evaluate their biological property as Multi Drug Resistance modulators (inhibitors of Pgp). For this purpose, we developed a novel synthetic route for the preparation of migrastatin-core analogues. Unfortunately, migrastatin analogues failed to inhibit Pgp. For this reason, the synthesized compounds were also tested as inhibitors of cell migration, an important target in cancer metastasis. Biological evaluation of Migrastatin analogues. Cell migration is involved in several physiological processes. On other hand, cell migration is also involved in other pathological processes such as metastasis. (5) Synthesized migrastatin analogues were found to inhibit cell migration in human breast cancer and canine cancer cell lines. (6) In collaboration with researchers at the Beatson Institute in Glasgow, we observed that in vivo migrastatin analogue treatment enhance cell-cell adhesion and therefore antagonize metastasis. (7) Final results and their potential impact and use In conclusion, we develop a scalable route for the preparation of migrastatin-core analogues. We also provided materials to collaborators who carried out a study in vivo related to the mechanism by which this class of compounds inhibits tumour cell migration. We expect that these results have significant impact in the scientific community devoted to the study of cancer metastasis and cell migration in pathological conditions. References (1) Borowski, E.; BontempsGracz, M.; Piwkowska, A. Acta Biochim. Pol., 2005, 52, 609. (2) Robert, J.; Jarry, C. J. Med. Chem. 2003, 46, 4805. (3) Hiller, K.; Melzig, M. F. Lexikon der Arzneipflanzen und Drogen; Spektrum Akademischer Verlag: Heidelberg, Germany, 1999. (4) (a) Corea, G.; Fattorusso, E.; Lanzotti, V.; Taglialatela-Scafati, O.; Appennino, G.; Ballero, M.; Simon, P. -N.; Dumontet, C.; Di Pietro, A. J. Med. Chem. 2003, 46, 3395; (b) Corea, G.; Fattorusso, E.; Lanzotti, V.; Motti, R.; Simon, P. -N.; Dumontet, C.; Pietroio, A. D.; Planta Med. 2004, 70, 657; (c) Corea, G.; Fattorusso, E.; Lanzotti, V.; Motti, R.; Simon, P.-N.; Dumontet, C.; Di Pietro, A. J. Med. Chem. 2004, 47, 988; (d) Barile, E.; Borriello, M.; Pietro, A. D.; Doreau, A.; Fattorusso, C.; Fattorusso, E.; Lanzotti, V. Org. Biomol. Chem. 2008, 6, 1756–1762. (5) Carmeliet, P.; Nat. Med. 2003, 9, 653. (6) Majchrzak, K.; Lo Re, D.; Gajewska, M.; Bulkowska, M.; Homa, A.; Pawłowski, K.; Motyl, T.; Murphy, P.; Król, M. PlosOne, 2013, 8, e76789. (7) Lo Re, D.; Zhou, Y.; Nobis, M.; Anderson, K.; Murphy, P.V. ChemBioChem, 2014, 15, 1459.

Data: CORDIS, © European Union

Project objective

AbstractJatrophane are natural compounds isolated from Euphorbia (Euphorbiaceae, spurge family). More than 150 jathrophane have been isolated so far. The general structure is an highly functionalized trans-bicyclo[10.3.0]pentadecane skeleton. Jatrophanes possess a variety of different biological activities such as inhibitory activity on the mammalian mitochondrial respiratory chain, cell cleavage arrest, cytotoxicity against various human cancer cell lines, antiviral activity, antiplasmodial activity, microtubule interaction and cytotoxicity against human cancer cell lines. Most notably, they are inhibitors of the P-glycoprotein (Pgp), a membrane protein whose major function is the active transport of amphiphatic xenotoxins out of the cytoplasm. The over expression of the multi-drug resistance protein 1 (MDR1) gene (which encode for Pgp) contributes to the resistance of cancer cells against a large spectrum of anticancer drugs. Only natural occurring jatrophane have been investigated as modulator of multidrug resistance so far. Despite the large number of jatrophane isolated and the promising biological properties, the preparation this class of compounds can be regarded as a synthetic and biological challenge. The fellow has already an excellent background in synthetic chemistry. This project will allow him to increase his experience and knowledge in natural products chemistry, carbohydrate chemistry, development of bioactive compounds as well as enhance his synthetic experience. He proposes to join NUI Galway which is strategically developing strength in Biomedical Research, Cancer and Glycoscience, thus helping an objective 1 region of Europe to develop its research programme. NUI GAlway will also offer a series of transferrable skills and personal development courses to Dr. Lo Re. Both the scientific and personal training will contribute to the maturing of Dr. Lo Re to becoming an independent researcher.

Original text from CORDIS.

Participants

  • UNIVERSITY OF GALWAY · GalwayCoordinatorIreland

Links

Data: CORDIS, © European Union